Qualigen Therapeutics, Inc. (QLGN)
- Previous Close
0.0986 - Open
0.1000 - Bid 0.1018 x 100
- Ask --
- Day's Range
0.0955 - 0.1040 - 52 Week Range
0.0750 - 0.7830 - Volume
1,584,037 - Avg. Volume
2,804,203 - Market Cap (intraday)
2.785M - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6400 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
www.qlgntx.comRecent News: QLGN
View More
Performance Overview: QLGN
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QLGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QLGN
View MoreValuation Measures
Market Cap
2.70M
Enterprise Value
4.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-75.07%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.27M
Diluted EPS (ttm)
-1.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
118.69k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.66M
Research Analysis: QLGN
View MoreCompany Insights: QLGN
QLGN does not have Company Insights